{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:20:18Z","timestamp":1785817218666,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA198999"],"award-info":[{"award-number":["CA198999"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Protoc"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41596-022-00698-3","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T16:04:46Z","timestamp":1654099486000},"page":"1818-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Formulation of two lipid-based membrane\u2013core nanoparticles for FOLFOX combination therapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2893-912X","authenticated-orcid":false,"given":"Jianfeng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-8283","authenticated-orcid":false,"given":"Leaf","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1021\/cr100449n","volume":"112","author":"R Ghosh Chaudhuri","year":"2012","unstructured":"Ghosh Chaudhuri, R. & Paria, S. Core\/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chem. Rev. 112, 2373\u20132433 (2012).","journal-title":"Chem. Rev."},{"key":"698_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2020.05.005","volume":"156","author":"J Guo","year":"2020","unstructured":"Guo, J. & Huang, L. Membrane-core nanoparticles for cancer nanomedicine. Adv. Drug Deliv. Rev. 156, 23\u201339 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","volume":"142","author":"J Li","year":"2010","unstructured":"Li, J., Chen, Y. C., Tseng, Y. C., Mozumdar, S. & Huang, L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 142, 416\u2013421 (2010).","journal-title":"J. Control. Release"},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","volume":"158","author":"J Li","year":"2012","unstructured":"Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 158, 108\u2013114 (2012).","journal-title":"J. Control. Release"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.biomaterials.2017.07.007","volume":"141","author":"TJ Goodwin","year":"2017","unstructured":"Goodwin, T. J. et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials 141, 260\u2013271 (2017).","journal-title":"Biomaterials"},{"key":"698_CR6","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","volume":"11","author":"K Hu","year":"2017","unstructured":"Hu, K. et al. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano 11, 4916\u20134925 (2017).","journal-title":"ACS Nano"},{"key":"698_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10893-8","volume":"10","author":"M Hu","year":"2019","unstructured":"Hu, M. et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat. Commun. 10, 2993 (2019).","journal-title":"Nat. Commun."},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","volume":"31","author":"CJ Allegra","year":"2013","unstructured":"Allegra, C. J. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359\u2013364 (2013).","journal-title":"J. Clin. Oncol."},{"key":"698_CR9","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501\u20133508 (2013).","journal-title":"J. Clin. Oncol."},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler, J. P. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25, 2198\u20132204 (2007).","journal-title":"J. Clin. Oncol."},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand, C. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2014a GERCOR study. J. Clin. Oncol. 24, 394\u2013400 (2006).","journal-title":"J. Clin. Oncol."},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1021\/acsnano.0c01676","volume":"14","author":"J Guo","year":"2020","unstructured":"Guo, J., Yu, Z., Das, M. & Huang, L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 14, 5075\u20135089 (2020).","journal-title":"ACS Nano"},{"key":"698_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01297-0","volume":"20","author":"J Guo","year":"2021","unstructured":"Guo, J. et al. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Mol. Cancer 20, 10 (2021).","journal-title":"Mol. Cancer"},{"key":"698_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","volume":"14","author":"B Gustavsson","year":"2015","unstructured":"Gustavsson, B. et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorectal Cancer 14, 1\u201310 (2015).","journal-title":"Clin. Colorectal Cancer"},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ijc.20452","volume":"112","author":"R Banerjee","year":"2004","unstructured":"Banerjee, R., Tyagi, P., Li, S. & Huang, L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer 112, 693\u2013700 (2004).","journal-title":"Int. J. Cancer"},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jconrel.2020.04.040","volume":"323","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. J. Control. Release 323, 431\u2013441 (2020).","journal-title":"J. Control. Release"},{"key":"698_CR17","first-page":"1751","volume":"13","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Vasodilator hydralazine promotes nanoparticle penetration in advanced desmoplastic tumors. ACS Nano 13, 1751\u20131763 (2019).","journal-title":"ACS Nano"},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ymthe.2018.11.012","volume":"27","author":"M Das","year":"2019","unstructured":"Das, M., Shen, L., Liu, Q., Goodwin, T. J. & Huang, L. Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer. Mol. Ther. 27, 507\u2013517 (2019).","journal-title":"Mol. Ther."},{"key":"698_CR19","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone, T. C., Suntharalingam, K. & Lippard, S. J. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116, 3436\u20133486 (2016).","journal-title":"Chem. Rev."},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1021\/nn403606m","volume":"7","author":"S Guo","year":"2013","unstructured":"Guo, S. et al. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 7, 9896\u20139904 (2013).","journal-title":"ACS Nano"},{"key":"698_CR21","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1016\/j.biomaterials.2014.05.045","volume":"35","author":"S Guo","year":"2014","unstructured":"Guo, S. et al. Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. Biomaterials 35, 7647\u20137653 (2014).","journal-title":"Biomaterials"},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1021\/nn5010815","volume":"8","author":"S Guo","year":"2014","unstructured":"Guo, S. et al. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8, 4996\u20135009 (2014).","journal-title":"ACS Nano"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1002\/adfm.201401076","volume":"24","author":"L Miao","year":"2014","unstructured":"Miao, L., Guo, S., Zhang, J., Kim, W. Y. & Huang, L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 24, 6601\u20136611 (2014).","journal-title":"Adv. Funct. Mater."}],"container-title":["Nature Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41596-022-00698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-022-00698-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-022-00698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T15:38:41Z","timestamp":1659541121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41596-022-00698-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1038\/s41596-022-00698-3","relation":{},"ISSN":["1754-2189","1750-2799"],"issn-type":[{"value":"1754-2189","type":"print"},{"value":"1750-2799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.H. is a consultant for PDS Biotechnology, Samyang Biopharmaceutical Co. and Stemirna. J.G. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}